Virotek Biosciences

What Virotek Biosciences does

Virotek Biosciences is a privately held Canadian biotech company headquartered in Markham, Ontario, operating with 1–10 employees under CEO Saeid Babaei. The company was originally established to deliver Health Canada-approved COVID-19 diagnostic testing, including a standard PCR test at $125, an express PCR test at $175, and rapid antigen tests starting at $35, with results delivered through a secure online portal. Distribution is hybrid: direct-to-consumer via the covidpcrtesting.com e-commerce site, supplemented by a network of partner pharmacies across Canada that serve as specimen collection points. Target customer segments are primarily international travelers requiring pre-departure documentation, with secondary use cases in workplace and school screening programs.

The business is transaction-based (pay-as-you-go per test) with no disclosed subscription, enterprise contracts, or recurring revenue layer. Revenue, headcount trends, and funding history are not publicly disclosed. In October 2025, Virotek executed a notable strategic pivot by deploying the AVITI24 multi-omic sequencing platform from Element Biosciences, becoming Canada's first commercial lab to operate the system. This positions the company to move beyond COVID-only testing into translational genomics research and precision health services, a fundamentally different buyer profile and revenue model from its existing consumer testing business. The company holds Health Canada approval for its COVID-19 PCR testing and operates a single laboratory facility in Markham; no patents, awards, or named institutional customers are disclosed in available data.

Name

Virotek Biosciences

Legal name

VIROTEK BIOSCIENCE

Website

https://covidpcrtesting.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Virotek Biosciences is a Health Canada-approved Markham, Ontario lab offering COVID-19 PCR and rapid antigen tests to consumers and partner pharmacies, and recently became Canada's first commercial deployer of the AVITI24 multi-omic sequencing platform for precision health.

Ownership category

akta.pro rank

Product category

COVID-19 Diagnostic Testing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826), Services-Testing Laboratories (8734)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industries

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

Keywords

• COVID-19 PCR testing
• Rapid antigen testing
• Diagnostic testing services
• Multi-omic sequencing
• Travel health certification

Headquarters

HQ city

Markham

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. COVID-19 Testing Services: Virotek generates revenue through direct sale of COVID-19 PCR tests and rapid antigen tests to consumers. Tests are provided at partner pharmacy locations across Canada with results delivered through a secure portal. Revenue is transaction-based per test performed.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels1 record

Core offering

Virotek Biosciences provides Health Canada–approved COVID-19 diagnostic testing services—standard PCR, expedited PCR, and rapid antigen tests—primarily to international travelers needing certification, with turnkey workplace testing programs for employers and screening solutions for schools. The company also operates Canada's first commercial deployment of the AVITI24 multi-omic sequencing platform for translational genomics research. Distribution is through a direct-to-consumer e-commerce site (covidpcrtesting.com) and a national network of partner pharmacies.

Product overview

Virotek Biosciences operates a multi-offering portfolio consisting of COVID-19 diagnostic testing services and advanced genomic sequencing capabilities. The core testing products include COVID-19 PCR Tests (standard and express variants), Rapid Antigen Tests, and bundled combo packages for travelers and organizations. Additionally, Virotek has expanded into precision health through the AVITI24 Multi-Omic Sequencing Platform, making it Canada's first commercial lab to deploy this technology for translational genomics research. The company operates a network of partner pharmacies and clinics across Canada for specimen collection, while maintaining a centralized laboratory for advanced genomic analysis.

Differentiator

Problem solved

Functional benefit

Products and services

• Standard COVID-19 PCR Test

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

One partnership is on record.

• AVITI24 (Element Biosciences)coreTechnology or Integration · 22 October 2025Virotek Biosciences became Canada's first commercial lab to deploy the AVITI24 multi-omic sequencing platform for translational genomics research. The system enhances throughput, accuracy, and cost efficiency for genomic research, supporting various kinds of molecular profiling.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Others

• Element Biosciences: Manufacturer of the AVITI24 sequencing platform that Virotek deployed. Not a competitor but the strategic technology partner — comparable because Element's roadmap directly determines the assay menu and capabilities Virotek can offer on its precision health platform.
• Illumina (through service providers): Dominant sequencing platform vendor whose installed base powers most clinical and translational genomics services globally. Comparable as the alternative sequencing technology ecosystem Virotek's AVITI24 platform must compete against in attracting Canadian genomics customers.

Broad incumbents

• Eurofins Genomics: Global genomics and molecular diagnostics service provider with broad sequencing and PCR service offerings. Comparable as a competitor in the translational genomics services market where Virotek's AVITI24 platform will compete for Canadian research and pharma customers.
• LifeLabs: Canada's largest medical laboratory network offering routine and specialized diagnostic testing across all provinces. Comparable as a Canadian clinical lab operator with overlapping molecular diagnostic capabilities, though at vastly larger scale and breadth than Virotek's COVID-focused offering.
• Dynacare: Major Canadian clinical laboratory providing diagnostic testing and health solutions across multiple provinces. Direct comparability as a Canadian lab services provider with established specimen collection infrastructure that competes for the same healthcare and corporate testing budgets as Virotek.
• Randox Laboratories: International clinical diagnostics and testing laboratory with COVID-19 PCR test products and broader molecular diagnostic capabilities. Comparable as a diversified testing lab player competing for travel testing and broader diagnostic services demand.

Regional players

• The Doctor's Lab (TDLPATH): Independent medical laboratory offering diagnostic testing services primarily outside Canada. Comparable as a regional diagnostic lab operator with similar service portfolio (molecular diagnostics, clinical testing) targeting similar end-customers in healthcare and travel contexts.

Direct peers

• Switch Health: Canadian COVID-19 testing provider offering DTC PCR and rapid antigen tests with travel certification. Closely comparable business model — DTC e-commerce booking, partner pharmacy/clinic network, Health Canada approval, and travel-focused positioning — making it the most direct competitor to Virotek in Canada.
• Travel Safe Clinic: Canadian clinic offering COVID-19 PCR and rapid antigen testing specifically targeted at international travelers. Closely comparable in product mix, target customer (travelers needing certified results), and DTC delivery model.

Emerging players

• Myriad Genetics: Molecular diagnostics company focused on genetic testing for hereditary cancer, pharmacogenomics, and other precision health applications. Comparable in precision health / genomics services positioning, though operating at much larger scale and with proprietary assay content rather than a service-only model.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Virotek Biosciences